While the prevalence of Chinese products on the Indian market has risen since the price cap, the growth has remained marginal. Stents purchased before the price cap cost substantially higher than domestic products. Patients also opted for the goods more commonly, likely because of the belief that imported products licensed by the FDA were of higher quality. Despite the fact that these stents are now set at the same cost as domestic stents— making them cheaper than before— their use has dropped.

Around ten and twenty percent of domestically produced stents have spread across the industry, a gap created by the decline of imported stents. This may be an indication of the inability of foreign companies to sell at lower prices, although it may also be a case of patient convenience, as there have been no other large-scale reports of foreign consumer withdrawals.

The Indian products were claimed to perform well, although not approved by the FDA. Based on the cardiology group, Dr. Venkatesh noticed patterns of complications and defects with the stents remained unchanged. Nonetheless, owing to “stiffer, less elastic stents” and “rough-cut delivery systems” correlated with domestic products, he states the somewhat more difficult techniques— suggesting potentially lower quality products.